A New Second-Derivative Spectrophotometric Method for the Determination of Vildagliptin in Pharmaceutical Dosage Form

Subhadip C (1) , Nalanda Baby R (2) , Pridhvi Krishna G (3) , Suraj M (4) , Shyamdeo Kumar T (5)
(1) Department of Pharmaceutical Analysis, GITAM Institute of Pharmacy, GITAM University, Visakhapatnam-530045, India, India ,
(2) Department of Pharmaceutical Analysis, GITAM Institute of Pharmacy, GITAM University, Visakhapatnam-530045, India, India ,
(3) Department of Pharmaceutical Analysis, GITAM Institute of Pharmacy, GITAM University, Visakhapatnam-530045, India, India ,
(4) Department of Pharmaceutical Analysis, GITAM Institute of Pharmacy, GITAM University, Visakhapatnam-530045, India, India ,
(5) Department of Pharmaceutical Analysis, GITAM Institute of Pharmacy, GITAM University, Visakhapatnam-530045, India, India

Abstract

An accurate derivative spectrophotometric method was developed and validated for the determination of dipeptidyl peptidase inhibitor vildagliptin in the pharmaceutical dosage form. The second derivative of the UV spectra has enabled the estimation of vildagliptin absorbance at 217 nm without any interferences. Linearity, precision, accuracy, detection (LOD), and quantification (LOQ) limits were established for method validation. Calibration curve was linear in the range of 10-60 µg/mL with a regression coefficient of 0.998. The method was validated as per the International Conference on Harmonization (ICH Q2 (R1)). The limit of detection and the limit of quantification were found to be 2.06 µg/mL and 6.25 µg/mL, respectively. Intra and interday precision data illustrated that the method has acceptable reproducibility as the percentage relative standard deviation (RSD) was less than 2 %, which indicates the precision of the method. The recovery was 98.39 % by the standard addition method. The percentage assay of vildagliptin was 98.06 % which showed good applicability. The following results indicate that the procedure is accurate, precise, and reproducible while being simple and less time-consuming. The method was demonstrated to be adequate for routine analysis in quality control.

Full text article

Generated from XML file

References

Abu, D. W., Hamad, M., Mallah, E., Abu, D. A., Awad, R., Zakaria, Z., Arafat, T. 2018. Method development and validation of vildagliptin and metformin HCl in pharmaceutical dosage form by Reverse Phase-High Performance liquid Chromatography. International Journal of Pharmaceutical Sciences and Research, 9(7):2965–2972.

He, H., Tran, P., Yin, H., Smith, H., Batard, Y., Wang, L., Einolf, H., Gu, H., Mangold, J. B., Fischer, V., Howard, D. 2009. Absorption, metabolism, and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 37(3):536–544.

Jayaprakash, R., Natesan, S. K. 2017. Stability Indicating RP-HPLC Method Development and Validation for The Simultaneous Determination of Vildagliptin and Metformin in Pharmaceutical Dosage Form. International Journal of Pharmacy and Pharmaceutical Sciences, 9(3):150.

Lauster, C. D., Mckaveney, T. P., Muench, S. V. 2007. Vildagliptin: A novel oral therapy for type 2 diabetes mellitus. American Journal of Health-System Pharmacy, 64(12):1265–1273.

Mahesh, A., Sree, H. N., Bandar, E. S., Anroop, B. N., Katarigatta, N. V. 2017. Determination on vildagliptin in rat plasma by capillary electrophoresis tandem mass spectrometry: Its application to pharmacokinetic study. Indian Journal of Pharmaceutical Education and Research, 51(4):1–7.

Patil, K. R., Deshmukh, T. A., Patil, V. R. 2020. A stability-indicating HPTLC method development and validation for analysis of vildagliptin as bulk drug and from its pharmaceutical dosage form. International Journal of Pharmaceutical Sciences and Research, 11(5):2310–2316.

Q2, I. 2005. International Conference on Harmonization. Validation of analytical procedures: Text and methodology. Page: 17.

Sakthimanigandan, K., Ganesh, M., Kanthikiran, V., Sivakumar, T., Jang, H. 2015. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of Vildagliptin in rat plasma. Acta Chromatographica, 27(2):295–307.

Samer, H., Hanan, M., Youssef, A. 2019. Spectrophotometric method for the determination of vildagliptin in bulk and pharmaceutical dosage forms. International Journal of Pharmaceutical Sciences Review and Research, 58(2):117–120.

Seino, Y., Kuwata, H., Yabe, D. 2016. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. Journal of Diabetes Investigation, 7(1):102–109.

Uçaktürk, E. 2015. Development of Sensitive and Specific Analysis of Vildagliptin in Pharmaceutical Formulation by Gas Chromatography-Mass Spectrometry. Journal of Analytical Methods in Chemistry, pages 1–7.

Vaishali, P. P., Krishna, A. B., Mrunali, M. S., Dharti, M. P., Rakshita, S. P., Divya, M. D., Prachi, H. P. 2021. Development and validation of spectrophotometric estimation of vildagliptin through oxidative coupling reaction using MBTH reagent in a pharmaceutical dosage form. Research Journal of Pharmacy and technology, 14(1):2021–2035.

Authors

Subhadip C
Nalanda Baby R
nrevu@gitam.edu (Primary Contact)
Pridhvi Krishna G
Suraj M
Shyamdeo Kumar T
Subhadip C, Nalanda Baby R, Pridhvi Krishna G, Suraj M, & Shyamdeo Kumar T. (2021). A New Second-Derivative Spectrophotometric Method for the Determination of Vildagliptin in Pharmaceutical Dosage Form. International Journal of Research in Pharmaceutical Sciences, 12(4), 2610–2614. Retrieved from https://ijrps.com/home/article/view/527

Article Details

No Related Submission Found